Actym Therapeutics Extends Series A Financing with Additional $25.5M Closing
October 20, 2023
Source: drugdu
65
In a company press release, Actym Therapeutics announced that it has extended its Series A financing round with an additional close of $25.5 million, bringing the total Series A amount raised to $59.5 million. Co-led by Boehringer Ingelheim Venture Fund and Illumina Ventures, with GKCC LLC as a new investor, the new capital is expected to enable ACTM-838 into first-in-human oncology trial.
"We have advanced the STACT platform and defined a value-building clinical pathway that will allow us to translate our deep understanding of the tumor microenvironment into a novel approach to an effective and safe cancer treatment," said Christopher Thanos, PhD, CEO, co-founder, Actym Therapeutics. "We value the continued commitment from our current investors and welcome GKCC LLC into the syndicate. Through their combined support, we aim to bring innovative therapies to patients across multiple solid tumor indications."
Image Credit: Adobe Stock Images/Carlos Montes
Published on: October 19, 2023
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Pioneer Institute study finds IRA discourages non-opioid drug innovation May 3, 2024
- Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn May 3, 2024
- New study reveals global risk distribution of visceral leishmaniasis May 3, 2024
- Genetic associations of key genes in breast cancer pathogenesis May 2, 2024
- Medtronic wins FDA approval for Inceptiv closed-loop spinal cord stimulator May 2, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
